Comparative Pharmacology
Head-to-head clinical analysis: HEPARIN LOCK FLUSH versus PRADAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPARIN LOCK FLUSH versus PRADAXA.
HEPARIN LOCK FLUSH vs PRADAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heparin potentiates the activity of antithrombin III, inactivating thrombin and activated factor X (FXa), thereby preventing fibrin formation and thrombus propagation.
Direct thrombin inhibitor; binds reversibly to the active site of thrombin, preventing fibrinogen cleavage and subsequent thrombus formation.
10-100 units/mL solution, 1-2 mL flush intravascularly after each catheter use or daily when catheter is not in use; typical adult dose: 10-100 units per flush.
150 mg orally twice daily; for patients with CrCl 15-30 mL/min, 75 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life approximately 1-2 hours (mean 1.5 hours) at therapeutic doses; increases with dose; in renal failure, half-life prolonged up to 3-5 hours; clinical note: duration of effect short due to rapid clearance, requiring continuous infusion or frequent dosing.
12–17 hours (terminal); prolonged to 18–35 hours in severe renal impairment (CrCl <30 mL/min); supports twice-daily dosing
Primarily renal via glomerular filtration and tubular secretion; about 50% excreted unchanged in urine; remainder metabolized in the liver and reticuloendothelial system (heparinase); fecal elimination negligible (<5%).
Renal (80% unchanged); fecal/biliary (20% as inactive metabolites via P-glycoprotein-mediated secretion)
Category A/B
Category C
Anticoagulant
Anticoagulant